Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceuticals, Inc. (SPRY) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ARS Pharmaceuticals, Inc. (SPRY) following a significant stock drop. The investigation stems from the company's disclosure that its flagship product, Neffy®, received no new commercial formulary additions or payer-coverage decisions in a recent review cycle, contradicting earlier optimistic statements by executives. The law firm is encouraging affected stockholders to connect to assist with the investigation.
ARS Pharmaceuticals (SPRY) President awarded 898,456 long-term stock options
ARS Pharmaceuticals President Donn Casale has been granted 898,456 stock options to purchase Common Stock at an exercise price of $7.96 per share, expiring in 2036. This long-term incentive award vests 25% on June 1, 2027, with the remainder vesting monthly over the subsequent three years, aligning Casale's interests with shareholder value and encouraging retention.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ARS Pharmaceuticals, Inc. (ARS) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into ARS Pharmaceuticals, Inc. (ARS) following a sharp drop in its share price. This investigation stems from the disclosure that Neffy®, ARS's epinephrine nasal spray, received no new commercial formulary additions or payer-coverage decisions for the July 1, 2026 review cycle, despite prior optimistic projections from company executives. The firm is encouraging affected ARS stockholders to learn more and assist in the investigation.
SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud
Levi & Korsinsky is investigating ARS Pharmaceuticals (SPRY) for potential securities fraud after its stock dropped more than 23% due to Neffy® receiving no new commercial formulary additions in the July 2026 payer cycle. This comes after the company had previously guided investors toward achieving broad commercial coverage, including expectations of being on formulary for major payers by July 1, 2026. Shareholders who lost money are encouraged to contact Levi & Korsinsky for a free evaluation of their legal rights.
ARS Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of ARS Pharmaceuticals (SPRY)
Levi & Korsinsky, LLP has initiated an investigation into ARS Pharmaceuticals (NASDAQ: SPRY) following a significant drop in its stock price. The investigation stems from the company's disclosure that its flagship product, Neffy®, failed to secure new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle, despite prior management projections of widespread formulary inclusion. Shareholders who suffered losses are encouraged to contact Levi & Korsinsky for a legal rights discussion.
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Growth-Defensive Index
ARS Pharmaceuticals, Inc. (NasdaqGM:SPRY) has been removed from the Russell 2000 Growth-Defensive Index. The company is a biopharmaceutical firm focused on treatments for allergic reactions and is commercializing neffy, an epinephrine nasal spray approved in several regions for emergency treatment of anaphylaxis.
ARS Pharmaceuticals (SPRY) Is Down 11.5% After Losing Spots in Key Russell 2000 Defensive Indices
ARS Pharmaceuticals (SPRY) dropped 11.5% after its removal from the Russell 2000 Growth-Defensive and Defensive Indices, which could impact its visibility and index-linked ownership. Despite this, the company's core investment narrative remains centered on the commercial and regulatory execution of its product, neffy, with recent Health Canada approval expanding its global market reach. Investors are advised to consider the long-term potential of neffy's global rollout against the backdrop of increased commercial spending, ongoing net losses, and potential pressure from payer concessions.
SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has launched an investigation into ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) following a significant drop in its stock price. This investigation focuses on potential securities law violations after the company's flagship product, Neffy, failed to secure new formulary additions, contradicting prior optimistic statements from executives. Shareholders who suffered losses are encouraged to contact the Schall Law Firm for more information.
SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) on behalf of investors for alleged securities law violations. This investigation follows a sharp drop in ARS shares after its product Neffy failed to secure new formulary additions, contradicting prior optimistic statements from the company's executives. Shareholders who incurred losses are encouraged to contact the firm for a free consultation.
Price to earnings forward of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY
This article provides a financial data point for ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), specifically its price-to-earnings forward ratio. It notes that the market is closed and there are no trades, and the information is presented without specific values. The page primarily consists of navigational elements and disclaimers.
Enterprise value to revenue forward of ARS Pharmaceuticals, Inc. – BOATS:SPRY
This article focuses on the enterprise value to revenue forward for ARS Pharmaceuticals, Inc. (SPRY) as monitored by the Blue Ocean Alternative Trade System (BOATS). It presents financial data within the TradingView platform, specifically under the "Financials" section for the company.
Enterprise value to revenue forward of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY
The article title indicates a focus on the enterprise value to revenue forward metric for ARS Pharmaceuticals, Inc. (NASDAQ: SPRY). However, the provided content is almost entirely navigation links, financial data disclaimers, and links to various TradingView products and services, without actual financial data or analysis for ARS Pharmaceuticals.
Form 4 ARS Pharmaceuticals Inc For: 26 June By Investing.com
This article reports on a Form 4 filing for ARS Pharmaceuticals Inc. on June 26. These filings are mandatory disclosures of stock transactions by company insiders to the Securities and Exchange Commission, providing transparency into trading activities. The brief report highlights the date of the filing and mentions the company involved.
ARS Pharmaceuticals (NASDAQ: SPRY) grants 30,000 options to RA Capital-linked director
ARS Pharmaceuticals (NASDAQ: SPRY) has granted 30,000 stock options to an entity associated with RA Capital, specifically held by Dr. Peter Kolchinsky for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund II, L.P. These options have an exercise price of $10.54 per share, expire on June 23, 2036, and will vest fully on the earlier of June 24, 2027, or the company's 2027 annual meeting of stockholders. Any net proceeds from the exercise of these options will reduce advisory fees owed to RA Capital Management, L.P.
Price to sales forward of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY
This article provides financial data for ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or data-only page from TradingView, offering an overview of the company's financials without detailed analysis or commentary.
Price to earnings forward of ARS Pharmaceuticals, Inc. – BOATS:SPRY
The article provides financial information for ARS Pharmaceuticals, Inc. (SPRY) on the TradingView platform, specifically focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed for this stock.
Director at ARS Pharmaceuticals (SPRY) receives 30,000 stock options
ARS Pharmaceuticals director Brent L. Saunders was granted 30,000 stock options with an exercise price of $10.54 per share, expiring on June 23, 2036. The options will vest fully on the earlier of June 24, 2027, or the company’s 2027 annual meeting of stockholders. This transaction, categorized as neutral in sentiment, was reported to the SEC via a Form 4 filing.
ARS Pharmaceuticals (SPRY) director Saqib Islam granted 30,000 stock options at $10.54
ARS Pharmaceuticals director Saqib Islam was granted 30,000 stock options at an exercise price of $10.54 per share. These options will vest in full on the earlier of June 24, 2027, or the company's 2027 annual meeting of stockholders, and will expire on June 23, 2036. This grant was reported via a Form 4 SEC filing, indicating a compensation award rather than a market trade.
ARS Pharmaceuticals (SPRY) director receives 30,000 stock options at $10.54 strike
ARS Pharmaceuticals director Phillip M. Schneider was granted 30,000 stock options with an exercise price of $10.54 per share on June 24, 2026, as compensation. These options will vest in full by June 24, 2027, or the 2027 annual stockholder meeting, and are set to expire on June 23, 2036. This transaction is a grant and not an open-market purchase or sale of shares.
ARS Pharmaceuticals (SPRY) director option grant tied to OrbiMed
ARS Pharmaceuticals' director, Peter A. Thompson, was granted 30,000 stock options with an exercise price of $10.54 and an expiration date of June 23, 2036. These options will fully vest by June 24, 2027, or by the company's 2027 annual meeting. A notable condition is that any economic benefits derived from these options must be transferred to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will then relay them to OrbiMed Private Investments VI, LP.
Price to sales forward of ARS Pharmaceuticals, Inc. – BOATS:SPRY
This article provides financial information for ARS Pharmaceuticals, Inc. (SPRY) on the Blue Ocean Alternative Trade System (BOATS), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or partial financial data page from TradingView, offering a glimpse into the company's valuation metrics.
How Does ARS Pharmaceuticals' (SPRY) Neffy Coverage Stall Reframe Its Path to Cash-Flow Break-Even?
ARS Pharmaceuticals (SPRY) recently announced a stall in major commercial insurance coverage for its epinephrine nasal spray, Neffy, though it did secure additional Medicaid coverage. Despite this, the company reaffirmed its path to cash-flow break-even in 2027, supported by current Neffy business and reduced operating expenses. This situation highlights the critical role of payer access in ARS Pharmaceuticals' long-term financial stability and investment narrative.
Enterprise value to EBIT forward of ARS Pharmaceuticals, Inc. – BOATS:SPRY
This article provides the enterprise value to EBIT forward for ARS Pharmaceuticals, Inc. (SPRY) on the Blue Ocean Alternative Trade System (BOATS). It presents financial data for the company, accessible through TradingView.
Shareholders at ARS Pharmaceuticals (SPRY) back board, auditor and annual say-on-pay
ARS Pharmaceuticals (SPRY) shareholders voted at their 2026 Annual Meeting to re-elect three Class III directors, ratify Ernst & Young LLP as the independent registered public accounting firm, and approve the compensation of named executive officers on an advisory basis. They also determined that future advisory votes on executive compensation should occur annually. These decisions reflect shareholder confidence in the company's governance, financial oversight, and executive pay practices.
ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins
ARS Pharmaceuticals (NASDAQ: SPRY) reaffirmed its goal to achieve cash-flow breakeven in 2027, despite failing to secure new commercial formulary coverage for its epinephrine nasal spray Neffy in the July 1 cycle. The company lowered its projected 2026 operating expenses to $248 million, focusing on tighter cost controls and prioritizing commercial investments. While analyst William Blair noted investor focus on broader coverage, especially from CVS, ARS Pharma highlighted that Neffy is still widely available and Florida Medicaid has expanded access.
Cantor Fitzgerald keeps Overweight on ARS Pharmaceuticals stock
Cantor Fitzgerald reiterated its Overweight rating and $30.00 price target for ARS Pharmaceuticals (NASDAQ:SPRY) despite a recent formulary update indicating delays for Neffy's unrestricted formulary inclusion until January 1, 2027. The firm believes ARS Pharmaceuticals has strategies for Neffy's adoption and expects ARS-02 for Chronic Spontaneous Urticaria (CSU) to be a more significant product with higher margins. Analysts generally hold a Strong Buy consensus, projecting sales growth despite the company's quick cash burn, as highlighted by InvestingPro.
ARS Pharmaceuticals (SPRY) Misses Neffy Coverage Expansion, Is The Stock Still Cheap?
ARS Pharmaceuticals (SPRY) announced that its Neffy nasal spray did not secure expanded commercial insurance coverage in the recent review cycle, impacting expectations for its market reach. Despite this setback, the stock is trading at a significant discount to analyst targets and intrinsic value, leading to a debate on whether it's truly undervalued or if the market is already pricing in future growth challenges. Analysts suggest a "disruptive duo" narrative with competitor Aquestive Therapeutics against EpiPen, potentially leading to a 3x+ valuation re-rating for SPRY, but warn of slow Neffy uptake and margin pressures.
ARS Pharma sees neffy cash flow breakeven path in 2027
ARS Pharmaceuticals reported no new commercial formulary additions for neffy in the July 1, 2026 cycle but reaffirmed its path to cash-flow breakeven in 2027 by reducing 2026 operating expenses. The company also announced that Florida added neffy to its unrestricted Medicaid formulary and expects interim data from its Phase 2b CSU trial in Q4 2026. Despite a 24.09% stock decline following the news due to the lack of new formulary additions, ARS Pharma emphasizes ongoing payer discussions and neffy's continued demand growth, along with the significant future growth potential of the CSU market.
ARS Pharmaceuticals Provides Commercial and Financial Updates
ARS Pharmaceuticals announced that while no new commercial formulary additions for neffy® (epinephrine nasal spray) were secured for the July 1, 2026 cycle, the company continues payer discussions and has seen expanded state Medicaid coverage, including Florida. The company has reduced its 2026 cash-based operating expenses to $248 million and reaffirms its path to cash-flow breakeven in 2027, driven by neffy's base business and potential expansion into treating chronic spontaneous urticaria (CSU), with interim Phase 2b CSU data expected in Q4 2026.
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy
ARS Pharmaceuticals (SPRY) shares plummeted over 23% after-hours following the company's announcement that it had not secured new major commercial insurance coverage for its Neffy nasal spray, effective July 1st. Despite this setback, the company reported securing additional Medicaid coverage and lowered its expected operating expenses for 2026 to $248 million, reaffirming its target to achieve cash flow break-even in 2027. Neffy, an epinephrine nasal spray, generated $72.2 million in U.S. net sales in 2025.
ARS Pharmaceuticals (SPRY) Guggenheim Securities Inaugural Healthcare Innovation Conference summary
ARS Pharmaceuticals (SPRY) presented at the Guggenheim Securities Inaugural Healthcare Innovation Conference, highlighting its nasal spray epinephrine product, neffy. The company discussed its rapid nasal absorption technology, strong financial position, and a recent European licensing agreement. Neffy, already approved in the U.S. and Europe, targets a significant unmet need in the allergy market, offering a needle-free alternative with a faster and more sustained response than intramuscular injections.
ARS Pharmaceuticals (SPRY) Cantor Global Healthcare Conference 2025 Summary
This article summarizes ARS Pharmaceuticals' discussion at the Cantor Global Healthcare Conference 2025, focusing on the launch and market dynamics of Neffy. Key points include Neffy's launch 10 months prior, a direct-to-consumer campaign starting mid-May with linear TV ads in July, and the increasing adoption by physicians. The company also detailed its marketing strategy, consumer engagement, and efforts to improve access, pricing, and payer coverage for Neffy.
SPRY Should I Buy
ARS Pharmaceuticals Inc (SPRY) is highlighted as a good buy for beginner long-term investors due to its innovative product pipeline, strong hedge fund interest, and positive analyst ratings. Despite a recent slight market decline and neutral technical indicators, analysts have set ambitious price targets, citing the disruptive potential of neffy and future products like ARS-2. The company is poised for significant growth driven by these product launches.
(SPRY) Risk Channels and Responsive Allocation
This article provides an AI-driven analysis for Ars Pharmaceuticals Inc. (SPRY), highlighting strong near and mid-term sentiment despite a weak long-term outlook. It presents institutional trading strategies including position, momentum, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The analysis aims to help investors optimize position sizing and control risk based on predictive AI models.
ARS Pharmaceuticals Inc (SPRY) Institutional Confidence
ARS Pharmaceuticals Inc (SPRY) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 97.47%, a 9.23% increase quarter-over-quarter. Ron Baron is the largest institutional shareholder, holding 1.20 million shares.
ARS Pharmaceuticals Inc (SPRY) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for ARS Pharmaceuticals Inc (SPRY), highlighting a strong buy analyst rating and a price target of $31.00. The company's earnings forecast score is 9.20, ranking it well within its industry. It also includes expected revenue for the next quarter and past and future EPS figures.
ARS Pharmaceuticals Inc (SPRY) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial health analysis of ARS Pharmaceuticals Inc (SPRY), noting its current score of 6.91 out of 10. The company's financial status is categorized as weak, but its operating efficiency is high, with a significant year-over-year revenue increase of 184.47% and a net profit increase of 78.60%. The analysis also highlights specific financial metrics like Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns, indicating that relevant data for some of these areas has not yet been disclosed by the company.
ARS Pharmaceuticals Inc (SPRY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for ARS Pharmaceuticals Inc (SPRY), focusing on regional contributions. For FY2025, relevant financial data has not yet been disclosed by the company. As of April 6, the revenue proportions by region indicate that 85.66% ($72.19M) of revenue comes from the United States, with the remaining 14.34% ($12.09M) from the rest of the world.
ARS Pharmaceuticals Inc (SPRY) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of ARS Pharmaceuticals Inc (SPRY) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock splits. Financial data, such as market cap and pricing, are also included.
SPRY - Why the Market is Wrong About the ARS Pharma vs. Aquestive "DUOPOLY"
The article argues that the market is mispricing ARS Pharmaceuticals (SPRY) by viewing its competition with Aquestive Therapeutics (AQST) as a zero-sum "duopoly" in the epinephrine market. Instead, it posits that both companies' non-invasive products (neffy and Anaphylm) will expand the total addressable market by addressing needle phobia, rather than just splitting the existing pie dominated by EpiPen. The author's conservative valuation model suggests a 3x+ upside for SPRY, aligning with Wall Street consensus, despite potential risks from PBMs and forthcoming competition.
ARS Pharmaceuticals CCO Eric Karas sells $250,000 in stock
ARS Pharmaceuticals' Chief Commercial Officer, Eric Karas, sold 25,000 shares of common stock worth $250,000 after exercising stock options at a lower price. This transaction was part of a Rule 10b5-1 trading plan. Despite the sale, InvestingPro analysis suggests the stock, SPRY, appears undervalued, and Cantor Fitzgerald recently raised its price target for the company.
Ars Pharmaceuticals CLO Alexander Fitzpatrick sells $33,550 in stock By Investing.com
Alexander A. Fitzpatrick, Chief Legal Officer at ARS Pharmaceuticals Inc. (NASDAQ:SPRY), sold 3,355 shares of company stock for $33,550 on June 12, 2026, as part of a Rule 10b5-1 trading plan. Following the sale, Fitzpatrick directly holds 90,910 shares. This insider transaction occurs while SPRY shares are trading at $9.75, showing a 14% return over the last week, and the company, despite being unprofitable, is considered slightly undervalued by InvestingPro analysis.
ARS Pharmaceuticals (SPRY) legal chief sells 3,355 shares in planned trade
Alexander A. Fitzpatrick, Chief Legal Officer of ARS Pharmaceuticals (SPRY), sold 3,355 shares of common stock at $10.00 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, leaving him with 90,910 shares. The Form 4 filing details the planned sale and confirms his remaining direct ownership.
ARS Pharmaceuticals, Inc. SEC Filing
This article reports on an SEC Form 144 filing by ARS Pharmaceuticals, Inc. (SPRY), indicating a proposed sale of 25,000 shares of common stock with an aggregate market value of $250,000. The shares were acquired through a stock option exercise, and the sale is scheduled for June 12, 2026, on NASDAQ.
ARS Pharmaceuticals CCO Eric Karas sells $250,000 in stock
Eric Karas, CCO of ARS Pharmaceuticals Inc., sold 25,000 shares of common stock for $250,000 on June 12, 2026, after exercising options to acquire the same number of shares. This transaction was conducted under a Rule 10b5-1 trading plan. Despite a recent loss per share in Q1 2026, the company saw revenue exceed projections, and Cantor Fitzgerald raised its price target for ARS Pharmaceuticals to $30.00.
[Form 4] ARS Pharmaceuticals, Inc. Insider Trading Activity
ARS Pharmaceuticals' Chief Commercial Officer, Eric Karas, conducted a pre-arranged stock transaction by exercising options to buy 25,000 shares at $1.50 each and then selling all 25,000 shares at $10.00 each through an open-market sale. This transaction, executed under a Rule 10b5-1 trading plan adopted in December 2025, resulted in a net sale of $250,000 and leaves Karas with 12,176 directly held common shares.
Insider Sell: Eric Karas Sells 25,000 Shares of ARS Pharmaceuticals Inc (SPRY)
Eric Karas, Chief Commercial Officer of a subsidiary of ARS Pharmaceuticals Inc, sold 25,000 shares of SPRY on June 12, 2026. This transaction leaves him with 12,176 shares. The company, focused on therapies for severe allergic reactions, has seen 10 insider sells and no insider buys over the past year.
From Clinical To Market: Managing Pharma's Most Challenging Transition
This article discusses the challenges pharmaceutical companies face transitioning from drug development to commercialization. Author Richard Lowenthal, CEO of ARS Pharmaceuticals, shares lessons learned from Neffy's approval, emphasizing the need for strategic, operational, and cultural shifts beyond just regulatory success. He highlights that commercial preparedness creates value, culture is a significant risk, and continuous, intentional learning is crucial for navigating market complexities.
ARS Pharmaceuticals, Inc. (SPRY) soars 7.1%: Is further upside left in the stock?
This article reports that ARS Pharmaceuticals, Inc. (SPRY) stock has risen by 7.1%. It poses a question to investors about whether more upside potential remains for the stock.
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies
ARS Pharmaceuticals has partnered with former NFL quarterback Drew Brees to raise awareness about living with severe allergies, including food allergies. Brees, who was diagnosed with peanut and other food allergies, will help educate the public on the importance of preparedness, including the use of epinephrine and treatment options like neffy® (epinephrine nasal spray). The collaboration aims to encourage discussions between patients, caregivers, and healthcare providers about managing severe allergic reactions and anaphylaxis.
